 Bradley Haverkos
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, T-Cell | 8 | 2024 | 23 | 3.110 |
Why?
| | Lymphoma, T-Cell, Peripheral | 6 | 2024 | 16 | 2.820 |
Why?
| | Lymphoma | 5 | 2023 | 198 | 1.970 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 4 | 2024 | 9 | 1.800 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 6 | 2023 | 43 | 1.730 |
Why?
| | Herpesvirus 4, Human | 6 | 2023 | 157 | 1.580 |
Why?
| | Hematopoietic Stem Cell Transplantation | 10 | 2024 | 577 | 1.550 |
Why?
| | Epstein-Barr Virus Infections | 5 | 2023 | 95 | 1.540 |
Why?
| | Transplantation Conditioning | 10 | 2024 | 166 | 1.330 |
Why?
| | Skin Neoplasms | 6 | 2024 | 830 | 1.180 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2023 | 79 | 1.110 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 232 | 1.100 |
Why?
| | Lymphoma, B-Cell | 5 | 2024 | 103 | 1.050 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 6 | 2024 | 115 | 1.040 |
Why?
| | Hodgkin Disease | 2 | 2018 | 133 | 0.990 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2017 | 22 | 0.980 |
Why?
| | Graft vs Host Disease | 6 | 2024 | 240 | 0.820 |
Why?
| | Smiling | 1 | 2021 | 6 | 0.760 |
Why?
| | Thrombocytopenia | 1 | 2023 | 189 | 0.740 |
Why?
| | DNA, Viral | 3 | 2017 | 347 | 0.700 |
Why?
| | Face | 1 | 2021 | 165 | 0.670 |
Why?
| | Cord Blood Stem Cell Transplantation | 4 | 2024 | 99 | 0.650 |
Why?
| | Natural Killer T-Cells | 1 | 2020 | 65 | 0.640 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2024 | 957 | 0.620 |
Why?
| | Hematology | 1 | 2019 | 15 | 0.620 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 198 | 0.590 |
Why?
| | Heterocyclic Compounds | 2 | 2017 | 18 | 0.580 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 756 | 0.560 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 149 | 0.550 |
Why?
| | Prognosis | 8 | 2024 | 3773 | 0.530 |
Why?
| | Burkitt Lymphoma | 3 | 2021 | 56 | 0.520 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 181 | 0.500 |
Why?
| | Antineoplastic Agents | 7 | 2023 | 2045 | 0.480 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 417 | 0.470 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1368 | 0.460 |
Why?
| | Viral Load | 1 | 2016 | 449 | 0.450 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 21 | 0.450 |
Why?
| | Immunotherapy, Adoptive | 4 | 2024 | 300 | 0.430 |
Why?
| | Remission Induction | 4 | 2024 | 274 | 0.420 |
Why?
| | Humans | 49 | 2024 | 129847 | 0.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1560 | 0.400 |
Why?
| | Adult | 22 | 2024 | 35634 | 0.380 |
Why?
| | Treatment Outcome | 14 | 2024 | 10241 | 0.370 |
Why?
| | Mycosis Fungoides | 2 | 2023 | 61 | 0.370 |
Why?
| | Rituximab | 6 | 2023 | 164 | 0.370 |
Why?
| | Survival Analysis | 6 | 2020 | 1271 | 0.340 |
Why?
| | Middle Aged | 22 | 2024 | 31177 | 0.330 |
Why?
| | Transplantation, Homologous | 4 | 2019 | 402 | 0.320 |
Why?
| | Aged | 18 | 2024 | 22107 | 0.320 |
Why?
| | Immunoblastic Lymphadenopathy | 2 | 2022 | 2 | 0.320 |
Why?
| | Transplantation, Autologous | 3 | 2020 | 213 | 0.310 |
Why?
| | Aged, 80 and over | 9 | 2024 | 7066 | 0.290 |
Why?
| | Anti-HIV Agents | 1 | 2014 | 757 | 0.280 |
Why?
| | Recurrence | 6 | 2024 | 1013 | 0.280 |
Why?
| | Salvage Therapy | 2 | 2019 | 136 | 0.270 |
Why?
| | Autografts | 2 | 2019 | 42 | 0.260 |
Why?
| | Benzylamines | 2 | 2017 | 41 | 0.250 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 2 | 2015 | 12 | 0.240 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 21 | 0.220 |
Why?
| | Retrospective Studies | 10 | 2024 | 14553 | 0.220 |
Why?
| | Male | 20 | 2024 | 63759 | 0.220 |
Why?
| | Myeloablative Agonists | 2 | 2020 | 21 | 0.210 |
Why?
| | Sezary Syndrome | 1 | 2023 | 44 | 0.210 |
Why?
| | Immunotoxins | 1 | 2023 | 54 | 0.200 |
Why?
| | Disease-Free Survival | 3 | 2021 | 647 | 0.200 |
Why?
| | Female | 18 | 2024 | 68829 | 0.200 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 209 | 0.190 |
Why?
| | Cyclophosphamide | 4 | 2023 | 234 | 0.180 |
Why?
| | T-Lymphocytes | 2 | 2020 | 1937 | 0.180 |
Why?
| | Allografts | 2 | 2020 | 137 | 0.180 |
Why?
| | Killer Cells, Natural | 2 | 2024 | 426 | 0.180 |
Why?
| | Prospective Studies | 4 | 2022 | 7158 | 0.170 |
Why?
| | Young Adult | 9 | 2024 | 12467 | 0.170 |
Why?
| | Antigens, CD19 | 3 | 2024 | 120 | 0.150 |
Why?
| | Combined Modality Therapy | 3 | 2016 | 1201 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.150 |
Why?
| | Lymphoproliferative Disorders | 1 | 2018 | 54 | 0.140 |
Why?
| | Etoposide | 3 | 2023 | 148 | 0.140 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 190 | 0.140 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 69 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 39 | 0.140 |
Why?
| | Asparaginase | 1 | 2016 | 29 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2018 | 214 | 0.130 |
Why?
| | Antigens, CD34 | 1 | 2017 | 88 | 0.130 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 73 | 0.130 |
Why?
| | Doxorubicin | 3 | 2023 | 329 | 0.130 |
Why?
| | In Situ Hybridization | 1 | 2017 | 296 | 0.130 |
Why?
| | HIV Infections | 2 | 2021 | 2730 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 753 | 0.130 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 627 | 0.130 |
Why?
| | Biopsy | 2 | 2018 | 1089 | 0.130 |
Why?
| | Cell Count | 1 | 2017 | 318 | 0.130 |
Why?
| | Immunotherapy | 1 | 2020 | 596 | 0.130 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1282 | 0.120 |
Why?
| | Europe | 1 | 2016 | 363 | 0.120 |
Why?
| | North America | 1 | 2016 | 294 | 0.120 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2016 | 19 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 858 | 0.120 |
Why?
| | Ohio | 1 | 2015 | 152 | 0.120 |
Why?
| | Biomarkers | 2 | 2016 | 3971 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2024 | 4896 | 0.120 |
Why?
| | Drug Resistance | 1 | 2015 | 165 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1514 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 382 | 0.110 |
Why?
| | Adolescent | 5 | 2024 | 20451 | 0.110 |
Why?
| | B-Lymphocytes | 1 | 2018 | 816 | 0.100 |
Why?
| | United States | 5 | 2023 | 13913 | 0.100 |
Why?
| | Vincristine | 2 | 2023 | 108 | 0.100 |
Why?
| | Medicare | 1 | 2018 | 719 | 0.100 |
Why?
| | Academic Medical Centers | 1 | 2015 | 483 | 0.100 |
Why?
| | Prednisone | 2 | 2023 | 234 | 0.100 |
Why?
| | Gene Expression | 1 | 2017 | 1465 | 0.090 |
Why?
| | Genomics | 1 | 2017 | 716 | 0.090 |
Why?
| | Skin | 1 | 2016 | 725 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2023 | 129 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1327 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1161 | 0.080 |
Why?
| | Melphalan | 2 | 2020 | 29 | 0.080 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 87 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1686 | 0.080 |
Why?
| | Vidarabine | 2 | 2020 | 32 | 0.080 |
Why?
| | Whole-Body Irradiation | 2 | 2020 | 76 | 0.080 |
Why?
| | Registries | 3 | 2020 | 1903 | 0.070 |
Why?
| | Fetal Blood | 2 | 2020 | 318 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 851 | 0.070 |
Why?
| | Cohort Studies | 3 | 2021 | 5444 | 0.060 |
Why?
| | Lactate Dehydrogenases | 1 | 2023 | 5 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 283 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2024 | 121 | 0.050 |
Why?
| | Disease Management | 2 | 2018 | 592 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 232 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2023 | 437 | 0.050 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 119 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 258 | 0.040 |
Why?
| | Busulfan | 1 | 2020 | 15 | 0.040 |
Why?
| | Aminoquinolines | 1 | 2020 | 21 | 0.040 |
Why?
| | Carmustine | 1 | 2020 | 50 | 0.040 |
Why?
| | Cytarabine | 1 | 2020 | 57 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 148 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1872 | 0.040 |
Why?
| | Central Nervous System | 1 | 2021 | 256 | 0.040 |
Why?
| | Acetates | 1 | 2019 | 100 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1597 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 339 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 29 | 0.040 |
Why?
| | Ganciclovir | 1 | 2018 | 52 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 264 | 0.040 |
Why?
| | Quinazolines | 1 | 2019 | 243 | 0.040 |
Why?
| | Virus Activation | 1 | 2018 | 88 | 0.040 |
Why?
| | Virus Latency | 1 | 2018 | 84 | 0.040 |
Why?
| | Zidovudine | 1 | 2018 | 78 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 166 | 0.040 |
Why?
| | Standard of Care | 1 | 2016 | 71 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1501 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 282 | 0.030 |
Why?
| | Dexamethasone | 1 | 2018 | 352 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1248 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2015 | 37 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2018 | 228 | 0.030 |
Why?
| | Steroids | 1 | 2015 | 158 | 0.030 |
Why?
| | Mice | 2 | 2023 | 16983 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 304 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2019 | 719 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1690 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1269 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 2888 | 0.020 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 596 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1434 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3161 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 640 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 9801 | 0.020 |
Why?
| | Animals | 2 | 2023 | 35409 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4077 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2511 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3269 | 0.020 |
Why?
| | Child | 1 | 2024 | 20962 | 0.010 |
Why?
|
|
Haverkos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|